A cycloheximide time course established that CTLA4 has an extremely short half-life (<1 h) in all three cell lines, which makes it one of the most short-lived transmembrane proteins described in human cancer cells (Fig. 1, A and B) (Li et al., 2021; Rusilowicz-Jones et al., 2022). This evidence concerns the gene CTLA4 and cancer.